Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity-27 month follow-up results from Turkey


Yetik H., Gunay M., Sirop S., Salihoglu Z.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol.253, no.10, pp.1677-1683, 2015 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 253 Issue: 10
  • Publication Date: 2015
  • Doi Number: 10.1007/s00417-014-2867-0
  • Journal Name: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.1677-1683
  • Keywords: Retinopathy of prematurity (ROP), Anti-VEGF, Bevacizumab, Intravitreal injection, ZONE-I, COUNTRIES, LASER

Abstract

To study the efficacy of intravitreal bevacizumab (IVB) injection as a single treatment for retinopathy of prematurity (ROP).